Recon: FDA denies Regenxbio’s gene therapy for Hunter syndrome; Moderna signs deal to manufacture mRNA vaccines in Mexico

• Trump administration revives effort to launch pilot initiative reworking drug discount program (STAT)
• GLP-1s Likely TrumpRx Savings Focus Over Old, Genericized Products (Pink Sheet)
• The new childhood vaccine guidelines have a paid leave problem (STAT)
• 'Bat-sh*t crazy': Biopharma leaders unload on regulatory chaos (Endpoints)
• FDA rejects Regenxbio's Hunter syndrome gene therapy (Endpoints)
• Measles cases in South Carolina rise by 13 to 933, state health department says (Reuters)
• FDA untitled letters target drug ads from Novo, argenx, Sobi (Fierce Pharma)

• Shanghai's Cascade gets $72M to pursue MASH, obesity and diabetes drugs (Endpoints)
• Hengrui, Kailera push obesity pill ahead on promising mid-stage China data (Endpoints)
• With scant data, RFK Jr. credits Trump tariffs for higher drug prices in Europe (Endpoints)
• Illumina Looks To Clinical Consumables And China Restart To Offset Intensifying NGS Price Pressure (MedTech Insight)
• EMA Backs Smarter Tool To Spot Pregnancy‑Related Medicine Risks (Pink Sheet)
• Moderna inks long-term pact with Mexico to bolster local mRNA vaccine supply (Fierce Pharma)

• The fallout from Novo vs. Hims (Endpoints)
• Abridge CTO talks Epic, Microsoft, and rebranding as ‘more than an AI scribe’ (STAT)
• Eczema drug from Nektar Therapeutics maintains skin responses in one-year study (STAT)
• Biotech doubles financing in quest to silence genes behind neurological diseases (STAT)
• Is AstraZeneca on track to meet its $80B revenue target? (Endpoints)
• CSL’s CEO Paul McKenzie exits after rough few years (Endpoints)
• AstraZeneca’s obesity pill hits in Phase 2, key cancer trials pushed back (Endpoints)
• Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial (Reuters)
• Novartis CEO pay soars 30% to $32M following record-breaking 2025 performance (Fierce Pharma)
• As Jakafi approaches generic competition, Incyte counts more on Opzelura (Fierce Pharma)

• Quest Diagnostics forecasts 2026 profit, revenue above estimates on lab test demand (Reuters)
• Baxter cuts roughly 90 jobs at IV solutions plant that recovered from Hurricane Helene (MedTech Dive)
• Stryker starts limited release of Mako RPS handheld knee robot (MedTech Dive)
• Philips Sets 3-Year Growth Plan And Ends 2025 On A Comparative High (MedTech Insight)

• US FDA to review decades-old food preservative in safety overhaul (Reuters)
• FDA must be more transparent about outbreak investigations (Food Safety News)

• Federal government turns to fresher data to rein in Medicare Advantage upcoding (STAT)
• National Cancer Institute studying ivermectin’s ‘ability to kill cancer cells,’ alarming career scientists (STAT)
• OHSU board votes to negotiate with NIH and possibly transform its primate center into an animal sanctuary (STAT)
• US House panel issues subpoenas to eight health insurers on alleged Obamacare fraud (Reuters)
• CVS Health keeps in place 2026 forecast, eyes topping it (Reuters)
• Registered EMS Agencies: The New Kid on the DEA Block (FDA Law Blog)